American Ginseng Extract Panax quinquefolius L. Is Safe in Long-Term Use in Type 2 Diabetic PatientsReport as inadecuate




American Ginseng Extract Panax quinquefolius L. Is Safe in Long-Term Use in Type 2 Diabetic Patients - Download this document for free, or read online. Document in PDF available to download.

Evidence-Based Complementary and Alternative MedicineVolume 2014 2014, Article ID 969168, 6 pages

Research Article

Centre for Applied Pharmacy, Faculty of Pharmacy and Biochemistry, University of Zagreb, 10 000 Zagreb, Croatia

Clinical Nutrition and Risk Factor Modification Centre, St. Michael’s Hospital, Li Ka Shing Knowledge Institute, Toronto, ON, Canada M5C 2T2

Departments of Nutritional Sciences and Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada M5S 3E2

Department of Endocrinology, Diabetes and Metabolic Disease, Dubrava University Hospital, University of Zagreb, 10 000 Zagreb, Croatia

Clinical Department of Laboratory Diagnostics, Dubrava University Hospital, University of Zagreb, 10 000 Zagreb, Croatia

Received 3 March 2014; Accepted 14 April 2014; Published 7 May 2014

Academic Editor: Chang-Gue Son

Copyright © 2014 Iva Mucalo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Aim. The objective of the present study was to test the safety of supplementation with the American ginseng AG interventional material as an adjunct to conventional therapy diet and-or medications in type 2 diabetes, using a double-blind, randomized, placebo-controlled, parallel design. Methods. Each participant received either AG 10% ginsenosides or placebo capsules 500 mg-meal = 3 g-day for a period of 12 weeks. Outcomes included measures of safety including kidney function urates and creatinine, liver function AST and ALT, and haemostatic function PV and INR. Results. Seventy-four participants with well-controlled type 2 diabetes sex: 28 M and 46 F, age: 63 ± 9.5, BMI: 32 ± 5, and HbA1c: 7 ± 1.3, randomized to either intervention or control group, completed the study. There was no change in any of the measures of safety between treatments from baseline. The number or severity of adverse events did not differ between the AG intervention and placebo. Conclusion. Following 12 weeks of supplementation with AG, safety was not compromised in a high cardiovascular disease CVD risk population of patients with type 2 diabetes. This demonstrated that safety is noteworthy, as reviews have continuously warned of possible adverse effects of ginseng consumption.





Author: Iva Mucalo, Elena Jovanovski, Vladimir Vuksan, Velimir Božikov, Željko Romić, and Dario Rahelić

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents